CEL-SCI Corp (CVM)
AMEXHealth CareBiotechnologySnapshot 2026-09-04
$1.63+1.24%
Close 2026-09-04 · 1-day change
AMEXHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CVM
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 | Sep 2019 | Sep 2018 | Sep 2017 | Sep 2016 | Sep 2015 | Sep 2014 | Sep 2013 | Sep 2012 | Sep 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | — | — | — | — | — | — | — | — | — | — | — | — | 0.3 | 0.2 | 0.3 | — |
| Total Revenues | — | — | — | — | — | — | — | — | — | — | — | — | 0.3 | 0.2 | 0.3 | — |
| Operating Expenses & Income | ||||||||||||||||
| R&D Expenses | 14.8 | 15.9 | 18.2 | 22.5 | 25.4 | 23.1 | 17.8 | 12.7 | 10.9 | 15.6 | 17.4 | 19.2 | 15.3 | 12.7 | 10.4 | 11.7 |
| Operating Income | (22.3) | (24.8) | (26.4) | (31.5) | (36.1) | (36.2) | (29.0) | (20.2) | (16.8) | (21.4) | (23.6) | (32.4) | (25.7) | (19.9) | (17.2) | (18.0) |
| Earnings from Continuing Operations | ||||||||||||||||
| Interest Expense | 0.4 | 0.6 | 0.7 | 0.7 | 1.1 | — | 1.2 | — | — | — | — | 0.1 | 0.2 | 0.2 | 0.3 | 0.3 |
| Interest & Investment Income | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.1 | 0.2 |
| Net Interest Expenses | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.1 | 0.2 |
| Other Non-Operating Income / Expenses | — | — | — | — | — | — | — | — | — | — | (1.9) | (2.0) | (0.0) | (0.1) | (0.1) | — |
| EBT, Incl. Unusual Items | — | — | — | — | — | — | (30.3) | — | — | — | — | — | — | — | — | — |
| Earnings from Continuing Operations | — | — | — | — | — | — | — | — | — | — | (23.6) | — | — | — | — | — |
| Net Income | ||||||||||||||||
| Net Income | (22.7) | (25.4) | (27.6) | (32.4) | (36.7) | (36.4) | (30.3) | (22.1) | (31.8) | (14.4) | (11.5) | (34.7) | (27.4) | (9.2) | (15.5) | (25.7) |
| Per Share | ||||||||||||||||
| Basic EPS | — | — | — | — | (0.87) | (0.90) | (0.82) | (0.71) | (1.87) | (1.83) | (2.37) | (10.51) | (12.10) | (0.30) | (0.70) | (1.28) |
| Diluted EPS | (1.87) | (6.27) | (0.51) | (0.73) | (0.87) | (0.90) | (0.82) | (0.71) | (1.87) | (1.91) | (2.37) | (10.51) | (12.21) | (0.66) | (0.78) | (1.49) |
| Basic Weighted Avg Shares | — | — | — | — | 43.1 | 40.7 | 36.8 | 31.2 | 17.0 | 7.9 | 4.9 | 3.3 | — | — | 251.8 | 208.5 |
| Diluted Weighted Avg Shares | 12.1 | 4.1 | 54.0 | 44.5 | 43.1 | 40.7 | 36.8 | 31.2 | 17.0 | 7.9 | 4.9 | 3.3 | — | — | 251.8 | 208.5 |
| Supplemental | ||||||||||||||||
| EBITDA | — | (20.9) | (22.4) | (27.5) | (32.2) | (34.0) | (26.8) | (19.6) | (16.1) | (20.8) | (23.0) | (31.7) | (24.9) | (19.5) | (16.7) | (17.5) |
| EBIT | (22.3) | (24.8) | (26.4) | (31.5) | (36.1) | (36.2) | (29.0) | (20.2) | (16.8) | (21.4) | (23.6) | (32.4) | (25.7) | (19.9) | (17.2) | (18.0) |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.